search
Back to results

The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Infliximab
Sponsored by
Taizhou Mabtech Pharmaceutical Co.,Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy subject (male) between the ages of 18 and 45 years.
  • Subject with a body weight of ≥50 kg and ≤ 80 kg and a BMI between 19.0~26.0 kg/m2 (both inclusive);
  • Healthy as determined by pre-study medical history, physical examination, vital signs and 12-lead electrocardiogram;

Exclusion Criteria:

  • Those who have surgered 4 weeks before signing the informed consent;
  • Those with mental, respiratory, cardiovascular, digestive, urinary, reproductive, skeletal and motor, blood, endocrine, nervous and other system diseases, or those with any previous immune diseases;
  • Those who have received any drug treatment (including prescription drugs, over-the-counter drugs, biological products, Traditional Chinese medicine, vitamins, dietary supplements, etc.) and health care products within 4 weeks before signing the informed consent;
  • Those who accepted biological drugs within 6 months before signing the informed consent, or accepted the TNF monoconal antibody drugs;
  • Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponema pallidum antibody is positive;
  • Either T cell immunospot test (T-SPOT) or antinuclear antibody is positive;
  • Those who have infected within 30 days before administration, or serious infection associated with hospitalisation and/or which required inrravenous antibiotics within 3 months before administration.
  • Vaccinated within 30 months before signing the informed conset, or plan to vaccinate during the trail;
  • Those who have used soft drugs within 3 months prior to signing the informed consent or hard drugs within 1 year prior to the trail; those who have positive drug abuse test results;
  • Those who drinking too much tea, coffee and/or caffeinated beverages (more than 8 cups, 250ml per cup) every day;
  • Those who have a blood donation history of 400 ml within 3 months, or 200 ml within 1 month;
  • Those who have a history of drug or food allergy, or are known to be allergic to any component of the test drug or latex, etc.
  • Those who are addicted to smoking or smoke more than 10 cigarettes per day on average within 6 months before signing the informed consent;
  • Alcoholics or regular drinkers within 3 months before the trail, i.e. those who drink more than 14 units of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits with 40% alcohol), or whose alcohol breath test is positive;
  • Those who plan to donate sperm within 6 months after the adminstration of the test drug;

Sites / Locations

  • Shanghai Xuhui Central Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

CMAB008

Remicade

Arm Description

Outcomes

Primary Outcome Measures

Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours After the Single Infusion of CMAB008/Remicade

Secondary Outcome Measures

Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade
Time of Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade
Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single Infusion of CMAB008/Remicade
Total Frequency of AE/SAE Within the Whole Time of the Study
Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected

Full Information

First Posted
February 26, 2021
Last Updated
October 8, 2021
Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04779892
Brief Title
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
Official Title
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
February 1, 2020 (Actual)
Primary Completion Date
June 15, 2020 (Actual)
Study Completion Date
June 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Biological: CMAB008 Biological: Remicade
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CMAB008
Arm Type
Experimental
Arm Title
Remicade
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Infliximab
Intervention Description
100mg/vial
Primary Outcome Measure Information:
Title
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours After the Single Infusion of CMAB008/Remicade
Time Frame
up to 1680 hours
Secondary Outcome Measure Information:
Title
Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade
Time Frame
up to 1680 hours
Title
Time of Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade
Time Frame
up to 1680 hours
Title
Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single Infusion of CMAB008/Remicade
Time Frame
up to 1680 hours
Title
Total Frequency of AE/SAE Within the Whole Time of the Study
Time Frame
up to 1680 hours
Title
Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected
Time Frame
up to 1680 hours

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy subject (male) between the ages of 18 and 45 years. Subject with a body weight of ≥50 kg and ≤ 80 kg and a BMI between 19.0~26.0 kg/m2 (both inclusive); Healthy as determined by pre-study medical history, physical examination, vital signs and 12-lead electrocardiogram; Exclusion Criteria: Those who have surgered 4 weeks before signing the informed consent; Those with mental, respiratory, cardiovascular, digestive, urinary, reproductive, skeletal and motor, blood, endocrine, nervous and other system diseases, or those with any previous immune diseases; Those who have received any drug treatment (including prescription drugs, over-the-counter drugs, biological products, Traditional Chinese medicine, vitamins, dietary supplements, etc.) and health care products within 4 weeks before signing the informed consent; Those who accepted biological drugs within 6 months before signing the informed consent, or accepted the TNF monoconal antibody drugs; Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponema pallidum antibody is positive; Either T cell immunospot test (T-SPOT) or antinuclear antibody is positive; Those who have infected within 30 days before administration, or serious infection associated with hospitalisation and/or which required inrravenous antibiotics within 3 months before administration. Vaccinated within 30 months before signing the informed conset, or plan to vaccinate during the trail; Those who have used soft drugs within 3 months prior to signing the informed consent or hard drugs within 1 year prior to the trail; those who have positive drug abuse test results; Those who drinking too much tea, coffee and/or caffeinated beverages (more than 8 cups, 250ml per cup) every day; Those who have a blood donation history of 400 ml within 3 months, or 200 ml within 1 month; Those who have a history of drug or food allergy, or are known to be allergic to any component of the test drug or latex, etc. Those who are addicted to smoking or smoke more than 10 cigarettes per day on average within 6 months before signing the informed consent; Alcoholics or regular drinkers within 3 months before the trail, i.e. those who drink more than 14 units of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits with 40% alcohol), or whose alcohol breath test is positive; Those who plan to donate sperm within 6 months after the adminstration of the test drug;
Facility Information:
Facility Name
Shanghai Xuhui Central Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200031
Country
China

12. IPD Sharing Statement

Learn more about this trial

The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety

We'll reach out to this number within 24 hrs